Table 1.
Clinical and laboratory features of 210 patients with myeloproliferative neoplasms, stratified by the clinical diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis (PMF)
| Variables | PV (n = 80) | ET (n = 80) | PMF (n = 50) | All patients (n = 210) |
|---|---|---|---|---|
| Age in years; median (range) |
61 (20–89) |
59 (19–94) |
60 (36–89) |
60 (19–94) |
| Age > 60 years; n (%) |
51 (63%) |
45 (56%) |
31 (62%) |
127 (60%) |
| Leukocytes, × 109/l; median (range) |
10.94 (1–42.41) |
9.94 (2.83–22.71) |
10.38 (0.69–92.67) |
10.43 (0.69–92.67) |
| Erythrocytes, × 1012/l; median (range) |
6.36 (2.22–9.93) |
4.53 (1.51–6.84) |
4.11 (1.97–9.36) |
5.15 (1.51–9.93) |
| Hemoglobin, g/dl; median (range) |
186.25 (73–245) |
132.94 (48–182) |
116.95 (44–278) |
150.22 (44–278) |
| Platelets, × 109/l; median (range) | 292.61 (56–715) | 774.89 (328–2887) | 416.30 (16–2890) | 509.47 (16–2890) |